Galderma Group N (GALD) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.061x

Based on the latest financial reports, Galderma Group N (GALD) has a cash flow conversion efficiency ratio of 0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF475.06 Million ≈ $600.61 Million USD) by net assets (CHF7.73 Billion ≈ $9.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Galderma Group N (GALD) defensive interval to measure how many days the company can operate on defensive assets alone.

Galderma Group N - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how Galderma Group N's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Galderma Group N Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Galderma Group N ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
KOMATSU LTD. SPONS. ADR 1 F:KOMA	N/A
People's Insurance of China Ltd SHG:601319	0.073x
Endesa SA MC:ELE	0.108x
Gold Fields Ltd ADR NYSE:GFI	0.329x
JD.com Inc. F:013C	-0.026x
Agilent Technologies Inc NYSE:A	0.054x
PT BK CE.AS.ADR/25 RP625 F:BZG	0.041x
EMCOR Group Inc NYSE:EME	0.000x

Annual Cash Flow Conversion Efficiency for Galderma Group N (2021–2024)

The table below shows the annual cash flow conversion efficiency of Galderma Group N from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Galderma Group N.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF7.79 Billion ≈ $9.85 Billion	CHF429.77 Million ≈ $543.34 Million	0.055x	+67.62%
2023-12-31	CHF4.52 Billion ≈ $5.71 Billion	CHF148.64 Million ≈ $187.92 Million	0.033x	+28.01%
2022-12-31	CHF4.13 Billion ≈ $5.23 Billion	CHF106.30 Million ≈ $134.39 Million	0.026x	-40.45%
2021-12-31	CHF4.14 Billion ≈ $5.24 Billion	CHF178.92 Million ≈ $226.21 Million	0.043x	--

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$51.35 Billion

CHF40.61 Billion CHF

Market Cap Rank

#738 Global

#11 in Switzerland

Share Price

CHF172.95

Change (1 day)

+0.46%

52-Week Range

CHF108.10 - CHF172.95

All Time High

CHF172.95